Penile cancer is a rare malignant disease.
Paclitaxel combined with
platinum is often used as a first-line chemotherapeutic regimen for late-stage
penile cancer, and there is no standard second-line treatment. Clinical trials of
immunotherapy for
penile cancer are ongoing. There are no reports on PD1 inhibitor treatment in metastatic penile
carcinoma patients with MMR/MSI status heterogeneity. A 68-year-old patient was hospitalized with bilateral inguinal
lymph node metastasis and local penile recurrence after
penile cancer surgery. The lesion of the right inguinal lymph node showed a mismatch-repair-deficient (dMMR)/
microsatellite instability-low (MSI-L) status. After 3 cycles of
sintilimab (a PD1 inhibitor) combined with
paclitaxel and
cisplatin, the partial response of the
tumor was evaluated. Subsequently,
sintilimab monotherapy was used as maintenance treatment for 2 months. However, The lesion of local penile recurrence showed mismatch repair proficient (pMMR)/microsatellite stability (MSS) status by secondary biopsy when progressed rapidly. Interestingly, after continued treatment with
sintilimab combined with
gemcitabine, the patient achieved a partial response again. We should be aware of the importance of secondary biopsy for different lesions to confirm the heterogeneity of MMR/MSI status. For
penile cancer patients with MMR/MSI status heterogeneity, PD1 inhibitors combined with
chemotherapy are safe and effective. Due to oligometastatic lesion progression caused only by the heterogeneity of MMR/MSI status, PD1 inhibitor cross-line
therapy can also be considered an appropriate treatment.